Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
805K
-
Number of holders
-
5
-
Total 13F shares, excl. options
-
26.8K
-
Shares change
-
+11.1K
-
Total reported value, excl. options
-
$18.5K
-
Value change
-
+$7.23K
-
Number of buys
-
4
-
Number of sells
-
-2
-
Price
-
$0.67
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q3 2023
8 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q3 2023.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 5 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.8K shares
of 805K outstanding shares and own 3.33% of the company stock.
Largest 10 shareholders include SUSQUEHANNA INTERNATIONAL GROUP, LLP (26.6K shares), UBS Group AG (69 shares), OSAIC HOLDINGS, INC. (61 shares), AllSquare Wealth Management LLC (21 shares), NATIONAL BANK OF CANADA /FI/ (20 shares), Federation des caisses Desjardins du Quebec (19 shares), BlackRock Inc. (0 shares), BANK OF AMERICA CORP /DE/ (0 shares), TD Waterhouse Canada Inc. (85 shares), and TORONTO DOMINION BANK (2 shares).
This table shows the top 5 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.